Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

References

• Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, Hay SI, Bedi N, Bensenor IM, Castaneda-Orjuela CA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23. doi:10.1016/S1473-3099(16)00026-8.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–07. doi:10.1038/nature12060.
   PubMed Web of Science ®Google Scholar
• Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41. doi:10.1016/S1473-3099(16)00146-8.
   PubMed Web of Science ®Google Scholar
• WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Switzerland: World Health Organization; 1997.
   Google Scholar
• Katzelnick LC, Harris E. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017;35(36):4659–69. doi:10.1016/j.vaccine.2017.07.045.
   PubMed Web of Science ®Google Scholar
• Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, Nisalak A, Khuntirat B, Jarman RG, Fernandez S, et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies. PLoS Negl Trop Dis. 2014;8(10):e3230. doi:10.1371/journal.pntd.0003230.
   PubMed Web of Science ®Google Scholar
• Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J. Live-attenuated tetravalent dengue vaccines: the needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017;35(42):5535–42. doi:10.1016/j.vaccine.2017.08.066.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–59. doi:10.1007/s00705-013-1645-3.
   PubMed Web of Science ®Google Scholar
• Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33(50):7100–11. doi:10.1016/j.vaccine.2015.09.108.
   PubMed Web of Science ®Google Scholar
• Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 2011;203(9):1282–91. doi:10.1093/infdis/jir012.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–E2053. doi:10.1073/pnas.1305227110.
   PubMed Web of Science ®Google Scholar
• Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, Sette A, Shresta S. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol. 2010;185(9):5405–16. doi:10.4049/jimmunol.1001709.
   PubMed Web of Science ®Google Scholar
• Rothman AL. DHIM supporting immunologic investigations and the identification of immune correlates of protection. J Infect Dis. 2014;209(Suppl 2):S61–S65. doi:10.1093/infdis/jiu111.
   PubMedGoogle Scholar
• Slifka MK. Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol. 2014;5:195. doi:10.3389/fimmu.2014.00195.
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Shresta S. Mouse models to study dengue virus immunology and pathogenesis. Front Immunol. 2014;5:151. doi:10.3389/fimmu.2014.00151.
   PubMed Web of Science ®Google Scholar
• Mathew A, Townsley E, Ennis FA. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol. 2014;9(3):411–25. doi:10.2217/fmb.13.171.
   PubMed Web of Science ®Google Scholar
• Rothman AL, Medin CL, Friberg H, Currier JR. Immunopathogenesis versus protection in dengue virus infections. Curr Trop Med Rep. 2014;1(1):13–20. doi:10.1007/s40475-013-0009-0.
   PubMedGoogle Scholar
• Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front Immunol. 2014;5:647. doi:10.3389/fimmu.2014.00647.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206. doi:10.1056/NEJMoa1506223.
   PubMed Web of Science ®Google Scholar
• WHO. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015(1). Safety of CYD-TDV dengue vaccine. Wkly Epidemiol Rec. 2015;90(34):421–23.
   PubMedGoogle Scholar
• Pang T, Mak TK, Gubler DJ. Prevention and control of dengue-the light at the end of the tunnel. Lancet Infect Dis. 2017;17(3):e79–e87. doi:10.1016/S1473-3099(16)30471-6.
   PubMedGoogle Scholar
• Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69:48–60.
   PubMed Web of Science ®Google Scholar
• Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg. 2003;69:1–4.
   PubMed Web of Science ®Google Scholar
• Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 2008;78:426–33.
   PubMed Web of Science ®Google Scholar
• Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg. 2011;85(2):341–51. doi:10.4269/ajtmh.2011.10-0501.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Eckels KH, Carletti I, De la Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013;88(1):73–88. doi:10.4269/ajtmh.2012.12-0361.
   PubMed Web of Science ®Google Scholar
• Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, et al. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014;91(1):119–28. doi:10.4269/ajtmh.13-0452.
   PubMed Web of Science ®Google Scholar
• Bauer K, Esquilin IO, Cornier AS, Thomas SJ, Quintero Del Rio AI, Bertran-Pasarell J, Morales Ramirez JO, Diaz C, Carlo S, Eckels KH, et al. A Phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in Puerto Rico. Am J Trop Med Hyg. 2015;93(3):441–53. doi:10.4269/ajtmh.14-0625.
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis. 2011;204(3):442–50. doi:10.1093/infdis/jir279.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013;31(41):4501–07. doi:10.1016/j.vaccine.2013.06.079.
   PubMed Web of Science ®Google Scholar
• Rothman AL, Currier JR, Friberg HL, Mathew A. Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. Vaccine. 2015;33(50):7083–90. doi:10.1016/j.vaccine.2015.09.104.
   PubMed Web of Science ®Google Scholar
• Watanaveeradej V, Simasathien S, Mammen MP Jr., Nisalak A, Tournay E, Kerdpanich P, Samakoses R, Putnak RJ, Gibbons RV, Yoon IK, et al. Long-term safety and immunogenicity of a tetravalent live-attenuated dengue vaccine and evaluation of a booster dose administered to healthy Thai children. Am J Trop Med Hyg. 2016;94(6):1348–58. doi:10.4269/ajtmh.15-0659.
   PubMed Web of Science ®Google Scholar
• Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255:27–40.
   PubMed Web of Science ®Google Scholar
• Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, Kirkpatrick BD. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis. 2012;6(7):e1742. doi:10.1371/journal.pntd.0001742.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Ennis FA, Rothman AL. Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining. J Immunol Methods. 2004;284:89–97.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, De Silva AD, Lindow JC, Diehl SA, Whitehead S, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015;89(1):120–28. doi:10.1128/JVI.02129-14.
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712–21. doi:10.1016/j.vaccine.2008.08.019.
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–30. doi:10.4049/jimmunol.0803903.
   PubMed Web of Science ®Google Scholar
• Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2015;212(10):1618–28. doi:10.1093/infdis/jiv258.
   PubMed Web of Science ®Google Scholar
• Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107(39):16922–27. doi:10.1073/pnas.1010867107.
   PubMed Web of Science ®Google Scholar
• Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VC, Lye DC, Leo YS, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol. 2013;87(5):2693–706. doi:10.1128/JVI.02675-12.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–15. doi:10.1056/NEJMoa066092.
   PubMed Web of Science ®Google Scholar
• Dorigatti I, Aguas R, Donnelly CA, Guy B, Coudeville L, Jackson N, Saville M, Ferguson NM. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015;33(31):3746–51. doi:10.1016/j.vaccine.2015.05.059.
   PubMed Web of Science ®Google Scholar
• Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother. 2013;9(7):1587–90. doi:10.4161/hv.24188.
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, De la Barrera R, Paolino KM, Toussaint JF, Lepine E, et al. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg. 2017;96(6):1325–37. doi:10.4269/ajtmh.16-0634.
   PubMed Web of Science ®Google Scholar
• Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg. 2003;69:12–16.
   PubMed Web of Science ®Google Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31(3):443–54. doi:10.1007/s10875-010-9490-6.
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J. 2010;29(6):e35–e46. doi:10.1097/INF.0b013e3181daf921.
   PubMed Web of Science ®Google Scholar
• Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, Ogundare E, Jongert E, Demoitié MA, Ofori-Anyinam O, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb). 2014;94(6):564–78. doi:10.1016/j.tube.2014.07.001.
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Arístegui J, Omeñaca F, Carmona A, Tejedor JC, Merino JM, García-Corbeira P, Walravens K, Bambure V, Moris P, et al. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: two open, uncontrolled studies. Hum Vaccin Immunother. 2015;11(10):2359–69. doi:10.1080/21645515.2015.1063754.
   PubMed Web of Science ®Google Scholar
• Precopio ML, Butterfield TR, Casazza JP, Little SJ, Richman DD, Koup RA, Roederer M. Optimizing peptide matrices for identifying T-cell antigens. Cytometry Part A. 2008;73A(11):1071–78. doi:10.1002/cyto.a.20646.
   Web of Science ®Google Scholar